Alpha Tau Is Building the Local Answer to Pancreatic Cancer’s Systemic Breakthrough
After encouraging early pancreatic data, demand for Alpha DaRT helped quadruple its IMPACT study from 12 patients to 48 as the company moves toward a pivotal trial.
Section
Science
Mechanisms, platforms, and the research that matters.
Daraxonrasib Approval Shifts Pancreatic Oncology from Cytotoxic Care to RAS-Targeted Precision
The FDA's landmark approval of Revolution Medicines' daraxonrasib (Rasonque) introduces the first multi-selective RAS(ON) tri-complex inhibitor for metastatic pancreatic adenocarcinoma, doubling overall survival over standard chemotherapy.
Why Bone Trauma Still Favors Hydrocodone Over Suzetrigine
Suzetrigine beat placebo on SPID48 in both pivotal acute-pain trials, then failed the superiority test against hydrocodone/acetaminophen, including a statistically significant loss in bunionectomy.
Brain Shuttle Platforms Tackle the Blood-Brain Barrier for Genetic Medicines
Conjugating antisense oligonucleotides to transferrin receptor transport vehicles achieves fifty-fold deeper brain penetration, challenging the standard of invasive spinal punctures.
What tumour-neuron synapses mean for glioblastoma - and why a local siRNA gel is the proposed answer
A 25 August Nature Biomedical Engineering paper shows malignant synapses concentrated at the GBM-brain interface, then tests an intracavitary TrkB-silencing hydrogel that more than doubled median survival in a mouse resection model.
What blocking Activin A means for FOP - Regeneron’s Pasatru and a disease that turns muscle into bone
FDA approved garetosmab on 19 August as the first FOP drug shown, in a placebo-controlled trial, to cut both new heterotopic-ossification lesions (by ≥90%) and clinician-assessed flare-ups.
Dual-Payload ADCs Tackle Heterogeneous Resistance in Solid Tumors
Coupling topoisomerase inhibitors and microtubule disruptors onto a single antibody scaffold exerts simultaneous multi-pathway cytotoxic pressure to block emergent drug resistance.
Epigenetic Editing Platforms Deliver Heritable Gene Silencing Without DNA Breaks
Engineered methyltransferases achieve durable transcriptional repression across multiple cell divisions without inducing double-strand chromosomal breaks or genomic translocations.
Vertex and CRISPR Push Casgevy into Pediatric Trials to Halt Early Organ Damage
Clinical investigators are expanding CRISPR gene editing into children aged five to eleven, aiming to reactivate fetal hemoglobin before cumulative sickle cell vasculopathy becomes irreversible.
Targeted Protein Degraders Overcome the 'Undruggable' Barrier with Molecular Glues
Recruiting cellular E3 ubiquitin ligases allows molecular glues and PROTACs to eliminate oncogenic transcription factors lacking classic small-molecule binding pockets.
Novartis Invests $250 Million in Radioligand Manufacturing Infrastructure
A dedicated radiopharmaceutical production complex in Indianapolis aims to secure domestic actinium-225 and lutetium-177 supplies as oncology demand surges.
In Vivo CAR-T Reaches First Clinical Proof-of-Concept in Lymphoma
Targeted lipid nanoparticles reprogramming circulating T cells inside the body achieved complete metabolic responses, bypassing complex ex vivo manufacturing logistics.